
Dendreon Corp. said it has received confirmation that the FDA will accept either a positive interim or final analysis of survival from its ongoing IMPACT (Immunotherapy for Prostate AdenoCarcinoma Treatment) study to amend the biologics license application (BLA) for sipuleucel-T (Provenge), a form of immunotherapy in late-stage development for the treatment of hormone-refractory prostate cancer.